Y-mAbs Therapeutics, Inc. - Common Stock (NQ:YMAB)

8.610 UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Y-mAbs Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

November 01, 2022

On Tuesday, 85 stocks hit new 52-week lows.

Via Benzinga

Analysts Slash Y-mAbs Therapeutics Price Targets As Uncertainty Looms Over Neuroblastoma Hopeful ↗

October 31, 2022

Via Benzinga

Where Y-mAbs Therapeutics Stands With Analysts ↗

October 31, 2022

Within the last quarter, Y-mAbs Therapeutics (NASDAQ:YMAB) has observed the following analyst ratings:

Via Benzinga

ON Semiconductor, Global Payments And Other Big Losers From Monday ↗

November 01, 2022

U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session.

Via Benzinga

Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday ↗

November 01, 2022

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product...

Via Benzinga

Lost Money in Y-mAbs Therapeutics, Inc.?

October 31, 2022

From Gibbs Law Group

Via Business Wire

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – YMAB

October 31, 2022

From The Rosen Law Firm, P.A.

Via Business Wire

S&P 500 Down 0.5%; Crude Oil Falls Sharply ↗

October 31, 2022

U.S. stocks traded lower toward the end of trading, with the S&P 500 dropping around 0.5% on Monday.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

October 31, 2022

During Monday's session, 96 stocks hit new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 31, 2022

Gainers

Via Benzinga

Why Global Payments Shares Are Trading Lower By Around 8%? Here Are 41 Stocks Moving In Monday's Mid-Day Session ↗

October 31, 2022

Gainers 1847 Holdings LLC (NASDAQ: EFSH) shares surged 72.7% to $3.25 after the company reported it sees over $60 million in revenue and over $7 million in cash flow from operations in 2023 from its...

Via Benzinga

Nasdaq Down Over 100 Points; Chicago PMI Drops Further ↗

October 31, 2022

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Monday.

Via Benzinga

US Stocks Start Week On Lower Note; Dow Dips Over 200 Points ↗

October 31, 2022

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 200 points on Monday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗

October 31, 2022

Upgrades

Via Benzinga

Grainger To Surge Over 11%? Plus This Analyst Predicts $230 For Caterpillar ↗

October 31, 2022

UBS raised the price target on Caterpillar Inc. (NYSE: CAT) from $225 to $230. Caterpillar shares fell 1.1% to $216.85 in pre-market trading.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 31, 2022

Gainers PLx Pharma (NASDAQ:PLXP) stock increased by 15.5% to $0.7 during Monday's pre-market session. The market value of their outstanding shares is at $20.3 million.

Via Benzinga

TuSimple, Y-mAbs Therapeutics And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗

October 31, 2022

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

October 31, 2022

Welcome back and get ready for another week of trading as we break down the biggest pre-market stock movers for Monday morning!

Via InvestorPlace

Why Quanergy Systems Shares Are Trading Sharply Lower; Here Are 28 Stocks Moving Premarket ↗

October 31, 2022

Gainers Selina Hospitality PLC (NASDAQ: SLNA) rose 31.9% to $19.90 in pre-market trading after dipping around 63% on Friday.

Via Benzinga

FDA's AdComm Gives Thumbs Down To Pediatric Cancer Therapy ↗

October 31, 2022

FDA's Oncologic Drugs Advisory Committee (ODAC) raised concerns regarding the efficacy of Y-mAbs Therapeutics Inc's (NASDAQ: YMAB) potential pediatric neuroblastoma treatment, omburtamab.

Via Benzinga

Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday ↗

October 28, 2022

Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 27, 2022

Gainers

Via Benzinga

Why UserTesting Shares Are Trading Higher By Around 93%? Here Are 53 Stocks Moving In Thursday's Mid-Day Session ↗

October 27, 2022

Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) gained 111% to $2.03 after the company announced it entered into a license agreement with Transcosmos Digital Technology for its Apromore process...

Via Benzinga

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

October 27, 2022

From The Schall Law Firm

Via Business Wire

Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday ↗

October 27, 2022

Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the...

Via Benzinga

Lost Money in Y-mAbs Therapeutics, Inc.?

October 26, 2022

From Gibbs Law Group

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

October 26, 2022

From The Schall Law Firm

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 26, 2022

Gainers

Via Benzinga

AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗

October 02, 2022

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.